153 related articles for article (PubMed ID: 30923665)
41. Functional implications of the conformational switch in AICD peptide upon binding to Grb2-SH2 domain.
Das S; Raychaudhuri M; Sen U; Mukhopadhyay D
J Mol Biol; 2011 Nov; 414(2):217-30. PubMed ID: 22001015
[TBL] [Abstract][Full Text] [Related]
42. Effect of pH and salt bridges on structural assembly: molecular structures of the monomer and intertwined dimer of the Eps8 SH3 domain.
Kishan KV; Newcomer ME; Rhodes TH; Guilliot SD
Protein Sci; 2001 May; 10(5):1046-55. PubMed ID: 11316885
[TBL] [Abstract][Full Text] [Related]
43. Potent inhibitory ligands of the GRB2 SH2 domain from recombinant peptide libraries.
Hart CP; Martin JE; Reed MA; Keval AA; Pustelnik MJ; Northrop JP; Patel DV; Grove JR
Cell Signal; 1999 Jun; 11(6):453-64. PubMed ID: 10400318
[TBL] [Abstract][Full Text] [Related]
44. The signal transduction through Grb2/Ash in hematopoietic cells.
Odai H; Hanazono Y; Sasaki K; Iwamatu A; Yazaki Y; Hirai H
Leukemia; 1997 Apr; 11 Suppl 3():405-7. PubMed ID: 9209406
[TBL] [Abstract][Full Text] [Related]
45. p56Lck and p59Fyn regulate CD28 binding to phosphatidylinositol 3-kinase, growth factor receptor-bound protein GRB-2, and T cell-specific protein-tyrosine kinase ITK: implications for T-cell costimulation.
Raab M; Cai YC; Bunnell SC; Heyeck SD; Berg LJ; Rudd CE
Proc Natl Acad Sci U S A; 1995 Sep; 92(19):8891-5. PubMed ID: 7568038
[TBL] [Abstract][Full Text] [Related]
46. Structural dynamics of the N-terminal SH2 domain of PI3K in its free and CD28-bound states.
Hosoe Y; Miyanoiri Y; Re S; Ochi S; Asahina Y; Kawakami T; Kuroda M; Mizuguchi K; Oda M
FEBS J; 2023 May; 290(9):2366-2378. PubMed ID: 36282120
[TBL] [Abstract][Full Text] [Related]
47. Structure-based design of compounds inhibiting Grb2-SH2 mediated protein-protein interactions in signal transduction pathways.
Fretz H; Furet P; Garcia-Echeverria C; Schoepfer J; Rahuel J
Curr Pharm Des; 2000 Dec; 6(18):1777-96. PubMed ID: 11102562
[TBL] [Abstract][Full Text] [Related]
48. Novel mode of ligand binding by the SH2 domain of the human XLP disease gene product SAP/SH2D1A.
Li SC; Gish G; Yang D; Coffey AJ; Forman-Kay JD; Ernberg I; Kay LE; Pawson T
Curr Biol; 1999 Dec; 9(23):1355-62. PubMed ID: 10607564
[TBL] [Abstract][Full Text] [Related]
49. Solution structure of the SH2 domain of Grb2/Ash complexed with EGF receptor-derived phosphotyrosine-containing peptide.
Tsuchiya S; Ogura K; Hatanaka H; Nagata K; Terasawa H; Mandiyan V; Schlessinger J; Aimoto S; Ohta H; Inagaki F
J Biochem; 1999 Jun; 125(6):1151-9. PubMed ID: 10348919
[TBL] [Abstract][Full Text] [Related]
50. Tyrosine phosphorylation of Grb2 by Bcr/Abl and epidermal growth factor receptor: a novel regulatory mechanism for tyrosine kinase signaling.
Li S; Couvillon AD; Brasher BB; Van Etten RA
EMBO J; 2001 Dec; 20(23):6793-804. PubMed ID: 11726515
[TBL] [Abstract][Full Text] [Related]
51. Grb2 SH3 binding to peptides from Sos: evaluation of a general model for SH3-ligand interactions.
Simon JA; Schreiber SL
Chem Biol; 1995 Jan; 2(1):53-60. PubMed ID: 9383403
[TBL] [Abstract][Full Text] [Related]
52. Binding affinity difference induced by the stereochemistry of the sulfoxide bridge of the cyclic peptide inhibitors of Grb2-SH2 domain: NMR studies for the structural origin.
Shi YH; Song YL; Lin DH; Tan J; Roller PP; Li Q; Long YQ; Song GQ
Biochem Biophys Res Commun; 2005 May; 330(4):1254-61. PubMed ID: 15823578
[TBL] [Abstract][Full Text] [Related]
53. Meltrin alpha cytoplasmic domain interacts with SH3 domains of Src and Grb2 and is phosphorylated by v-Src.
Suzuki A; Kadota N; Hara T; Nakagami Y; Izumi T; Takenawa T; Sabe H; Endo T
Oncogene; 2000 Nov; 19(51):5842-50. PubMed ID: 11127814
[TBL] [Abstract][Full Text] [Related]
54. Wiskott-Aldrich syndrome protein is associated with the adapter protein Grb2 and the epidermal growth factor receptor in living cells.
She HY; Rockow S; Tang J; Nishimura R; Skolnik EY; Chen M; Margolis B; Li W
Mol Biol Cell; 1997 Sep; 8(9):1709-21. PubMed ID: 9307968
[TBL] [Abstract][Full Text] [Related]
55. Solution structure and ligand-binding site of the carboxy-terminal SH3 domain of GRB2.
Kohda D; Terasawa H; Ichikawa S; Ogura K; Hatanaka H; Mandiyan V; Ullrich A; Schlessinger J; Inagaki F
Structure; 1994 Nov; 2(11):1029-40. PubMed ID: 7881903
[TBL] [Abstract][Full Text] [Related]
56. Crystal structure of the mammalian Grb2 adaptor.
Maignan S; Guilloteau JP; Fromage N; Arnoux B; Becquart J; Ducruix A
Science; 1995 Apr; 268(5208):291-3. PubMed ID: 7716522
[TBL] [Abstract][Full Text] [Related]
57. Small nonphosphorylated Grb2-SH2 domain antagonists evaluated by surface plasmon resonance technology.
Lung FD; Chang CW; Chong MC; Liou CC; Li P; Peach ML; Nicklaus MC; Lou BS; Roller PP
Biopolymers; 2005; 80(5):628-35. PubMed ID: 15660381
[TBL] [Abstract][Full Text] [Related]
58. Mutational investigation of the specificity determining region of the Src SH2 domain.
Bradshaw JM; Mitaxov V; Waksman G
J Mol Biol; 2000 Jun; 299(2):521-35. PubMed ID: 10860756
[TBL] [Abstract][Full Text] [Related]
59. Serum and insulin induce a Grb2-dependent shift in agonist affinity of beta-adrenergic receptors.
Shih M; Malbon CC
Cell Signal; 1998 Sep; 10(8):575-82. PubMed ID: 9794256
[TBL] [Abstract][Full Text] [Related]
60. Formation of Shc-Grb2 complexes is necessary to induce neoplastic transformation by overexpression of Shc proteins.
Salcini AE; McGlade J; Pelicci G; Nicoletti I; Pawson T; Pelicci PG
Oncogene; 1994 Oct; 9(10):2827-36. PubMed ID: 8084588
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
